Seth Wander, MD, PhD

Experts discuss the future of breast cancer treatment, emphasizing personalized approaches and the potential of new oral therapies to improve outcomes.

Experts discuss the implications of the SERENA-6 trial, highlighting the potential benefits of early oral SERD deployment in breast cancer treatment.

Researchers analyze real-world data on ESR1-mutated breast cancer treatments, revealing promising outcomes and insights for patient care strategies.

Explore the impact of elacestrant on ESR1-mutated breast cancer, revealing real-world data insights and genomic factors influencing treatment outcomes.

Experts discuss the integration of oral SERDs like elacestrant into clinical practice, highlighting their benefits for ESR1 mutant populations in breast cancer treatment.

Hope S. Rugo, MD, and Seth Wander, MD, PhD, discuss treatment selection after CDK4/6 inhibitor progression in advanced ER-positive breast cancer.

Seth Wander, MD, PhD discusses an overview of emerging data and evolving treatment strategies in advanced gastric and gastroesophageal cancers, with a focus on the role of biomarkers in guiding targeted and immunotherapy-based treatment. The presentation highlights clinical trial outcomes, testing considerations, and future directions shaping the personalized management of these patients.

Seth Wander, MD, PhD, discusses how he approaches therapeutic treatment for patients with ER+ advanced breast cancer in the clinic.

Seth Wander, MD, PhD, discusses the present limitations of first- and later-line therapy for HR+ metastatic breast cancer.

Seth Wander, MD, PhD, discusses the ELAINE-1, ELAINE-2, and ELAINE-3 trials in patients with ER-positive, HER2-negative metastatic breast cancer.

Seth Wander, MD, PhD, discusses findings from an analysis of baseline genomic alterations in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who were enrolled in the single-arm, phase 2 ELAINE-2 trial of lasofoxifene plus abemaciclib.

Seth Wander, MD, PhD, discusses the evaluation of vepdegestrant (ARV-471), a proteolysis targeting chimera estrogen receptor degrader, in patients with advanced estrogen receptor/HER2-negative breast cancer.

Seth Wander, MD, PhD, discusses challenges related to the ongoing platinum chemotherapy shortage for patients with breast cancer and other malignancies, as well as ways that oncologists and cancer centers can operate during the shortage to continue to provide appropriate care for patients.

Seth Wander, MD, PhD, discusses the investigation of resistance to CDK4/6 inhibitors and the role of NF1 mutations in breast cancer.